{
    "abstract": "Serum lipoprotein(a) [Lp(a)] is a risk factor of cardiovascular diseases. However, the relationship between the serum Lp(a) and clinical outcomes has been seldom studied in Chinese hospitalized patients with cardiovascular diseases.\nWe retrospectively collected the clinical data of hospitalized patients with cardiovascular diseases in the Cardiovascular Department of Dongguan People's Hospital from 2016 to 2021 through the electronic case system. Patients were divided into 4 groups based on Lp(a) quartiles: Quartile1 (\u2264\u200980.00\u00a0mg/L), Quartile 2 (80.01\u2009~\u2009160.90\u00a0mg/L), Quartile 3 (160.91\u2009~\u2009336.41\u00a0mg/L), Quartile 4 (>\u2009336.41\u00a0mg/L). Cox proportional hazard regression models were constructed to examine the relationship between Lp(a) and cardiovascular events.\nA total of 8382 patients were included in this study. After an average follow-up of 619 (320 to 1061) days, 1361 (16.2%) patients developed major adverse cardiovascular events, and 125 (1.5%) all-cause death were collected. The incidence of MACEs was 7.65, 8.24, 9.73 and 10.75 per 100 person-years in each Lp(a) quartile, respectively; the all-cause mortality was 0.48, 0.69, 0.64 and 1.18 per 100 person-years in each Lp(a) quartile, respectively. The multivariate Cox regression analysis suggested that high Lp(a) level was an independent risk factor for MACEs (HR: 1.189, [95% CI: 1.045 to 1.353], P\u2009=\u20090.030) and all-cause death (HR: 1.573, [95% CI: 1.009 to 2.452], P\u2009=\u20090.046).\nIn addition to traditional lipid indicators, higher Lp(a) exhibited higher risks of adverse cardiovascular events and death, indicated worse prognosis. Lp(a) may be a new target for the prevention of atherosclerotic diseases.",
    "authors": [
        {
            "affiliation": "Department of Cardiology, Dongguan People's Hospital, The First School of Clinical Medicine, Southern Medical University, Dongguan, 523059, Guangdong, People's Republic of China.",
            "firstname": "Tingting",
            "initials": "T",
            "lastname": "Min"
        },
        {
            "affiliation": "Department of Cardiology, Shenhe People's Hospital, The Fifth Affiliated Hospital of Jinan University, Heyuan, 517000, Guangdong, People's Republic of China.",
            "firstname": "Yilin",
            "initials": "Y",
            "lastname": "Yue"
        },
        {
            "affiliation": "Department of Cardiology, Dongguan People's Hospital, The First School of Clinical Medicine, Southern Medical University, Dongguan, 523059, Guangdong, People's Republic of China.",
            "firstname": "Xin",
            "initials": "X",
            "lastname": "Fan"
        },
        {
            "affiliation": "Department of Cardiology, Shenhe People's Hospital, The Fifth Affiliated Hospital of Jinan University, Heyuan, 517000, Guangdong, People's Republic of China.",
            "firstname": "Deguang",
            "initials": "D",
            "lastname": "Yang"
        },
        {
            "affiliation": "Department of Cardiology, Dongguan People's Hospital, The First School of Clinical Medicine, Southern Medical University, Dongguan, 523059, Guangdong, People's Republic of China. sysheng1023@sina.com.",
            "firstname": "Shaohui",
            "initials": "S",
            "lastname": "Su"
        },
        {
            "affiliation": "Department of Cardiology, Shenhe People's Hospital, The Fifth Affiliated Hospital of Jinan University, Heyuan, 517000, Guangdong, People's Republic of China. docvanhb@outlook.com.",
            "firstname": "Huaibin",
            "initials": "H",
            "lastname": "Wan"
        }
    ],
    "conclusions": "In addition to traditional lipid indicators, higher Lp(a) exhibited higher risks of adverse cardiovascular events and death, indicated worse prognosis. Lp(a) may be a new target for the prevention of atherosclerotic diseases.",
    "copyrights": "\u00a9 2024. The Author(s).",
    "doi": "10.1186/s40001-024-01957-7\n10.1111/j.1699-0463.1963.tb01808.x\n10.1016/0026-0495(75)90098-0\n10.1161/01.CIR.74.4.758\n10.1373/clinchem.2003.030031\n10.1161/CIRCULATIONAHA.117.032235\n10.1161/01.ATV.8.4.398\n10.1016/j.atherosclerosis.2009.12.036\n10.1161/01.ATV.11.3.629\n10.1016/j.thromres.2012.11.032\n10.1016/S0021-9150(99)00064-7\n10.1002/clc.4960270503\n10.1161/01.ATV.9.5.579\n10.1016/j.jacl.2019.04.010\n10.1016/0021-9681(87)90171-8\n10.1016/j.cll.2006.07.002\n10.1038/339303a0\n10.1021/bi00068a021\n10.1093/eurheartj/ehq386\n10.1016/0021-9150(81)90103-9\n10.1001/jama.296.11.1363\n10.1161/CIRCULATIONAHA.107.715698\n10.1016/j.jacasi.2022.08.015\n10.1016/0021-9150(91)90007-P\n10.1016/j.cca.2011.05.036\n10.1016/S0021-9258(18)90885-9\n10.1046/j.1365-2796.1998.00422.x\n10.1016/j.pharmthera.2010.01.008\n10.1056/NEJMoa2211023\n10.1093/eurheartj/ehx144\n10.1016/S0002-9149(99)00095-8\n10.1016/j.jacc.2020.10.008\n10.1194/jlr.R071233\n10.1161/01.ATV.5.3.265",
    "journal": "European journal of medical research",
    "keywords": [
        "Cardiovascular diseases",
        "Lipoprotein(a)",
        "Outcomes",
        "Retrospective study"
    ],
    "methods": null,
    "publication_date": "2024-08-17",
    "pubmed_id": "39152471\n14064818\n168455\n2944670\n15155542\n29133605\n2969235\n20106478\n1827591\n23260441\n10217351\n15188938\n2528948\n31147269\n3558716\n17110238\n2524666\n8485140\n20965889\n7470205\n16985228\n18086931\n36444328\n1837713\n21672532\n6236225\n9845859\n20153365\n36342163\n28444290\n10235090\n33272365\n27677946\n3158297",
    "results": "A total of 8382 patients were included in this study. After an average follow-up of 619 (320 to 1061) days, 1361 (16.2%) patients developed major adverse cardiovascular events, and 125 (1.5%) all-cause death were collected. The incidence of MACEs was 7.65, 8.24, 9.73 and 10.75 per 100 person-years in each Lp(a) quartile, respectively; the all-cause mortality was 0.48, 0.69, 0.64 and 1.18 per 100 person-years in each Lp(a) quartile, respectively. The multivariate Cox regression analysis suggested that high Lp(a) level was an independent risk factor for MACEs (HR: 1.189, [95% CI: 1.045 to 1.353], P\u2009=\u20090.030) and all-cause death (HR: 1.573, [95% CI: 1.009 to 2.452], P\u2009=\u20090.046).",
    "title": "The levels of serum lipoprotein(a) on clinical outcomes in Chinese hospitalized patients with cardiovascular diseases.",
    "xml": "<Element 'PubmedArticle' at 0x7885063a8810>"
}